

Joint Working	
Executive Summary	
Project title	
•	North Middlesex University Hospital NHS Trust
	"North Central London Anticoagulation pathway prioritisation service"
Project partners	North Middlesex University Hospital NHS Trust Daiichi Sankyo UK Ltd
Start date	March 2019

Project summary

North Middlesex University Hospital NHS Trust - "North Central London Anticoagulation pathway prioritisation service"


North Middlesex University Hospital NHS Trust and Daiichi Sankyo UK Ltd have entered into a joint working project entitled the "North Central London Anticoagulation pathway prioritisation service".

The overarching aim of this project is to optimise anticoagulation services to appropriately identify and treat the anticoagulation needs of domiciliary and care home patients, facilitated by the implementation of the NPSA anticoagulation guidelines supporting the safe initiation of DOACs. This will help adherence issues and improve the morbidity and mortality of this cohort of patients via a reduction in Stroke, Emergency and Elective Admissions and unexpected preventable deaths for patients in the North Central London area.

Expected benefits to patients and the NHS & Daiichi-Sankyo

This is a particular issue for domicilliary and care home patients in North Central London as the current patient pathway will be enhanced to properly address their needs and provide them with an anticoagulation service appropriate to their setting. This will save the NHS considerable sums of money by the prevention of Strokes and at the same time improve patient experience of local anticoagulation services.

DOP: March 2019. EDX/19/0094a



The benefit of this project for Daiichi-Sankyo is increase in reputational profile, and the opportunity to work in partnership with the NHS, in which the overall aim is to improve the health and well-being of patients with atrial fibrillation through improved detection and management of the condition.

Additionally, this Joint Working project is intended to create more opportunities for the appropriate use of medicines, including DAIICHI SANKYO UK's medicines in suitable patients in line with NICE treatment guidelines and the NPSA anticoagulation guidelines. If this improvement occurs, we are likely to see an increase in DOAC prescriptions including Lixiana.